Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 669.71M | 672.71M | 630.08M | 609.64M | 590.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 669.71M | 672.71M | 630.08M | 609.64M | 590.17M |
| Cost of Revenue | 837.57M | 838.57M | 811.01M | 757.94M | 752.98M |
| Gross Profit | -167.86M | -165.86M | -180.93M | -148.30M | -162.81M |
| SG&A Expenses | 347.20M | 348.20M | 342.15M | 335.88M | 329.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.20B | 1.21B | 1.17B | 1.11B | 1.10B |
| Operating Income | -531.06M | -535.06M | -544.08M | -505.18M | -513.65M |
| Income Before Tax | -605.23M | -571.23M | -576.36M | -530.04M | -546.77M |
| Income Tax Expenses | 3.69M | 3.69M | 3.20M | 2.63M | 2.55M |
| Earnings from Continuing Operations | -608.92 | -574.92 | -579.57 | -532.67 | -549.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -608.92M | -574.92M | -579.57M | -532.67M | -549.32M |
| EBIT | -531.06M | -535.06M | -544.08M | -505.18M | -513.65M |
| EBITDA | -497.05M | -500.05M | -508.32M | -469.27M | -477.50M |
| EPS Basic | -6.10 | -5.83 | -5.94 | -5.53 | -5.88 |
| Normalized Basic EPS | -3.60 | -3.62 | -3.69 | -3.44 | -3.63 |
| EPS Diluted | -6.10 | -5.83 | -5.94 | -5.53 | -5.88 |
| Normalized Diluted EPS | -3.60 | -3.62 | -3.69 | -3.44 | -3.63 |
| Average Basic Shares Outstanding | 398.73M | 394.43M | 390.21M | 385.94M | 374.06M |
| Average Diluted Shares Outstanding | 398.73M | 394.43M | 390.21M | 385.94M | 374.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |